Condition: Diffuse Cutaneous Systemic Sclerosis · Sponsor: Mediar Therapeutics
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This description comes directly from the study's public registry record.
Jeffrey Bornstein, MD · (617) 936-0960 · jeffrey@mediartx.com
Always discuss trial participation with your own doctor first.
| EncompaSSc site in Newport Beach, CA 92663 | Newport Beach, California, United States | Recruiting |
| EncompaSSc site in Clearwater, FL 33765 | Clearwater, Florida, United States | Recruiting |
| EncompaSSc site in Tampa, FL | Tampa, Florida, United States | Recruiting |
| EncompaSSc site in Baltimore, MD | Baltimore, Maryland, United States | Recruiting |
| EncompaSSc site in Boston, MA | Boston, Massachusetts, United States | Recruiting |
| EncompaSSc site in Dallas, TX | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07287670